Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely

Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition